Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Asparcam is a fixed-dose combination of potassium aspartate and magnesium aspartate, widely used in Eastern Europe and post-Soviet countries as a metabolic and electrolyte-balancing agent. It is designed to rapidly replenish potassium and magnesium deficiencies, thereby supporting myocardial metabolism, regulating cardiac rhythm, and maintaining electrolyte homeostasis. The aspartate anion acts as an endogenous carrier that facilitates the transport of potassium and magnesium ions across cell membranes into the intracellular space. Asparcam is commonly used as an adjuvant therapy for coronary heart disease, heart failure, and various cardiac arrhythmias, including those induced by cardiac glycoside overdose.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on potassium aspartate + magnesium aspartate.